Menin Inhibitors: Mushonga Unoshamisa weAcute Myeloid Leukemia

Acute myeloid leukemia (AML) chirwere chegomarara reropa chakaoma uye chakasiyana-siyana chinoratidzwa nekuwanda kwemasero e myeloid progenitor. Pasinei nekufambira mberi mukurapa, kurapa AML kuchiri kuoma, kunyanya kune varwere vane zvirwere zvakasiyana-siyana zvemajini. Zvidzidzo zvitsva zvakaratidzwa mujenari. Ropa kusimbisa kukosha kwemishonga inodzivirira Menin, vachiratidza kugona kwayo kuchinja kurapa kweAML.

Basa reEpigenetics muAML

Kugadziriswa kweEpigenetic, kwakadai seDNA methylation uye kugadziriswa kwehistone, kuchinja kunodzoserwa kunodzora kugadzirwa kwemajini pasina kuchinja kurongeka kweDNA. Kuchinja uku kunoita basa guru mukuvandudzwa kweAML. Kutarisa nzira idzi dzinodzoserwa dze epigenetic kunopa nzira itsva yekurapa.

MaHistones, mapuroteni akakosha ari muDNA packaging, anogadziriswa mushure mekushandurwa senge acetylation uye methylation, izvo zvinopesvedzera kunyorwa kwemajini. Menin, puroteni inogadzirwa neMEN1 gene, yakakosha pakugadziriswa kwe epigenetic. Inoshanda ne histone methyltransferase KMT2A nevamwe vadyidzani kuti itonge kutaurwa kwemajini. MuAML, Menin inobatsira zvirongwa zve oncogenic transcription, kunyanya kuburikidza nekuwedzerwa kwemajini eHOXA neMEIS1, ayo ari makuru muKMT2A-rearranged uye NPM1-mutated AML.

Menin Inhibitors: Kubudirira Mukurapa AML

MaMenin inhibitors mamorekuru madiki akasarudzwa zvakanyanya akagadzirirwa kukanganisa kusangana pakati peMenin neKMT2A, nokudaro achivhara nzira dzekunyora dzinokonzera oncogenic. MaInhibitor aya akaratidza kushanda kwakanaka muzvidzidzo zvepamberi pekiriniki uye zvekiriniki, kunyanya kune KMT2A-rearranged uye NPM1-mutated AML, iyo pamwe chete inomiririra chikamu chikuru chezviitiko zveAML.

Mushonga wekutanga weMenin inhibitor, revumenib (SNDX-5613), wakatenderwa kushandiswa mukiriniki, pamwe chete nedzimwe dzinoverengeka, dzinosanganisira ziftomenib (KO-539) uye bleximenib, dzichiedzwa mukiriniki. Kuedzwa kweAUGMENT-101 kwakaratidza kuti revumenib yakawana huwandu hwemhinduro (ORR) ye53% mu relapse or refractory (R/R) AML, ine migumisiro inogoneka yakadai seQTc prolongation and differentiation syndrome. Saizvozvowo, mhedzisiro yekutanga kubva mukuyedzwa kweKOMET-001 neKOMET-008 kwakaongorora ziftomenib yakaratidza mwero wekuregererwa uye ma profiles ekuchengetedza.

Mishonga yakasanganiswa iri kuongororwawo kuti iwedzere kushanda kweMenin inhibitors. Zvidzidzo zvinosanganisa revumenib nemishonga inobvisa methylation yakaita seazacitidine nevenetoclax zvakaratidza kuti huwandu hwemhinduro dziri kusvika 100% muvarwere vane AML vakagwinya uye vasina kukodzera, kunyange hazvo zvichidikanwa zvimwe zvidzidzo nemapoka makuru.

Nzira dzekuchengetedza uye dzeramangwana

Mishonga inodzivirira Menin inowanzoratidza kuchengetedzeka kwakanaka, uye migumisiro yakawanda inogona kugadziriswa uye kugadziriswa. Zviitiko zvakaipa zvinowanzo sanganisira zviratidzo zvemudumbu, cytopenias, uye differentiation syndrome. Kusarudzwa kwemishonga inodzivirira Menin ne ziftomenib neUS FDA kunoratidza kukosha kwemishonga inodzivirira Menin mukugadzirisa zvinodiwa zvisina kuzadzikiswa mukurapwa kweAML.

Ruzivo rwekiriniki runovimbisa pamusoro peMenin inhibitors runoratidza danho rekuchinja mukurapa kweAML, zvichipa tariro kuvarwere vane marudzi emumajini akambonetsa. Sezvo tsvakiridzo ichienderera mberi, mishonga iyi yakagadzirira kutsanangura patsva mwero wekutarisira AML.

BIOOCUS International Medical Center inoramba yakazvipira kushandisa nzira dzemazuva ano dzakadai seMenin inhibitors kuti ipe mishonga mitsva uye inoshanda kune varwere pasi rese.